Changchun Anwo High-tech Biopharmaceutical Co., Ltd. was established in March 2019 as a joint venture between Changchun High-tech Industrial Company and Iceland's Alvotech, with a 50%:50% share ratio. At its inception, the company had a registered capital of $200 million, covering a total land area of 106,000 square meters, with a building area of 90,000 square meters. Once the production facility meeting European and American standards is completed, it will achieve an annual production of 1.2 million units of adalimumab biosimilars, 740,000 units of bevacizumab biosimilars, and 800,000 units of aflibercept biosimilars. The company can not only meet the clinical and commercial development needs of its own antibody drugs but also undertake clinical and commercial production requirements for various antibody drugs from domestic and international clients.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
